bioAffinity Technologies, Inc. (BIAF) は上場企業です ヘルスケア セクターの Medical - Diagnostics & Research 業界で事業展開. 本社所在地は San Antonio, TX, アメリカ. 現CEOは Maria Zannes.
BIAF を有する IPO日 2022-09-01, 57 名の正社員, に上場 NASDAQ Capital Marke, 時価総額 $12.64M.
bioAffinity Technologies, Inc., a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company offers CyPath lung, a diagnostic test, for early detection of lung cancer. It also researches targeted therapies to treat cancer at the cellular level. The company was founded in 2014 and is based in San Antonio, Texas.
